Point mutations of the Mxi1 gene are rare in prostate cancers

Prostate

Volumn 29, Issue 3, 1996, Pages 191-193

  Kawamata, Norihiko ^a,d   Park, Dorothy ^a   Wilczynski, Sharon ^b   Yokota, Jun ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

10p24 25; myc; PCR SSCP; silent mutation; tumor suppressor gene

Indexed keywords

AMINO TERMINAL SEQUENCE; ARTICLE; CELL TRANSFORMATION; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE MYC; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; CELL CULTURE; GENETICS; MALE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR;

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DNA BINDING PROTEIN; HELIX LOOP HELIX PROTEIN; LEUCINE ZIPPER PROTEIN; MXI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; GENES, MYC; HELIX-LOOP-HELIX MOTIFS; HUMANS; LEUCINE ZIPPERS; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0029661946     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1     Document Type: Article

References (10)

1. Marcu KB, Bossone SA, Patel AJ: Myc function and regulation. Annu Rev Biochem 61: 809-860, 1992.
2. Blackwood EM, Eisenman RN: Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with Myc. Science 251: 1211-1217, 1991.
3. Ayer DE, Kretzner L, Eisenman RN: Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72: 211-22, 1993.
4. Zervos AS, Gyuris J, Brent R: Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232; Erratum: Cell 79, 1993.
5. Edelhoff S, Ayer DE, Zervos AS, Steingrimsson E, Jenkins NA, Copeland NG, Eisenman RN, Brent R, Disteche CM: Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19. Oncogene 9: 665-668, 1994.
6. Brothman AR, Peehl DM, Patel AM, McNeal JE: Frequency and pattern of karyotypic abnormalities in human prostatic cancer. Cancer Res 50: 3795-3803, 1990.
7. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV: Mutation of the MXI1 gene in prostate cancer. Nat Genet 9: 249-255, 1995.
8. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA: An amino-terminal domain of Mxi1 mediates anti-myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80: 777-786, 1995.
9. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning, a Laboratory Manual. (2nd ed.) Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
10. Kawamata N, Seriu T, Koeffler HP, Bartram CR: Molecular analysis of a family of cyclin-dependent kinase inhibitor genes; p16/MTS1/CDKN2/INK4A, p18/INK4C and p27/Kip1 in neuroblastomas. Cancer 77: 570-575, 1996.